Renovacor

Renovacor, headquartered in Philadelphia, USA, is a preclinical-stage biopharmaceutical company dedicated to developing treatments for cardiovascular diseases. Renovacor's core technology is based on recombinant adeno-associated virus (AAV) gene therapy, primarily targeting patients with dilated cardiomyopathy (DCM) caused by BAG3 gene mutations. Renovacor's leading gene therapy product aims to restore cardiac function in patients with symptomatic heart failure induced by BAG3 gene mutations.